New York (December 26th, 2012) - Cellceutix Corp. (OTCQB:CTIX - News), an early-stage developmental biopharmaceutical company that has acquired exclusive rights to eight different pharmaceutical compound candidates, is soaring in mid-day trading today, extending its gains from the previous trading sessions.
CTIX has been gaining momentum after an article published in the New York Times over the weekend heralded p53 drugs as the new age in cancer research. Leo Ehrlich, CEO of CTIX, said on Monday that he is pleased to see such a high profile article being written on the game changing impact that a p53 drug can have on treating cancers.
CTIX is currently trading 9.46% higher at $2.43 on volume of 1.23 million, which is five times the daily average volume of 418,413. CTIX has now gained more than 54% in the last three trading sessions. CTIX has, in fact, finished higher in each of the previous seven trading sessions. Technical indicators for the stock point to further gains.
Find out where CTIX could be headed by getting the free full report here:
Amarantus BioSciences Inc. (OTCQB:AMBS - News), a development stage biopharmaceutical company focused on the discovery and development of therapeutic proteins and biologics for the treatment of Parkinson’s disease, traumatic brain injury (TBI) and other human diseases, is rallying in mid-day trading today, extending its gains from the previous trading sessions.
AMBS is rallying in trading today after the company announced that it acquired all of the intellectual property assets from Power3 Medical Products. Gerald E. Commissiong, President and CEO of AMBS, said that the patents, patent applications and supporting data sets acquired as part of the transaction are a tremendous addition to the company’s intellectual property estate and fit well into the overall diagnostics strategy the company is pursuing to support its therapeutics programs.
AMBS is currently trading 22.11% higher at $0.0928 on volume of 11.66 million. The stock has gained nearly 57% in the last three trading sessions.
Find out if AMBS could maintain its bullish momentum by getting the free full report here: http://www.wallstreetreport.net/market-scan/?symbol=AMBS
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
Disclosure: WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
WALL STREET REPORT